Exagen Inc. (NASDAQ: XGN) announced the publication of a systematic review in Lupus Science & Medicine demonstrating the diagnostic performance of its AVISE Lupus algorithm across multiple patient populations.

The review analyzed biomarker data from 3,132 individuals across 14 academic medical centers in studies conducted between 2011 and 2025. According to the publication, the AVISE Lupus test identified 25% of systemic lupus erythematosus patients who were not detected by conventional serologic markers including anti-dsDNA, anti-Smith, and complements C3 and C4.

The study reported that AVISE Lupus demonstrated an area under the curve up to 0.90, specificity above 98%, and performed consistently across more than 1,200 SLE patients. The test showed diagnostic accuracy compared to conventional testing methods alone.

"Our findings show that AVISE fills a critical diagnostic gap in lupus diagnosis," said Daniel Wallace, co-author of the evaluation and co-director of the Lupus and Sjogren's Clinic at Kao Autoimmunity Institute at Cedars-Sinai.

The paper, titled "Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-Bound Complement Activation Products: A Systematic Evaluation," consolidated data from studies spanning 14 years. Exagen stated that more than 1 million patients have been tested using AVISE Lupus since its 2012 launch.

Exagen develops autoimmune diagnostic tests and operates a laboratory in San Diego County, California. The company's AVISE CTD product incorporates the AVISE Lupus algorithm for diagnosing autoimmune conditions including lupus, rheumatoid arthritis, and Sjögren's disease.